A Look Into Healthcare Sector Value Stocks
Portfolio Pulse from Benzinga Insights
Benzinga Insights has compiled a list of value stocks in the healthcare sector, including Agile Therapeutics, Chimerix, Cullinan Oncology, Ocuphire Pharma, and Kiniksa Pharmaceuticals. These stocks have low P/E multiples, indicating they may be undervalued.
May 22, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agile Therapeutics has a P/E of 0.04 and experienced an increase in earnings per share this quarter.
Agile Therapeutics has a low P/E ratio, indicating it may be undervalued. The increase in earnings per share this quarter suggests potential growth, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Chimerix has a P/E of 0.61 and its Q1 EPS remained unchanged from the previous quarter.
Chimerix has a low P/E ratio, indicating it may be undervalued. However, the unchanged EPS from the previous quarter suggests a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Cullinan Oncology has a P/E of 7.46 and experienced a decrease in earnings per share this quarter.
Cullinan Oncology has a low P/E ratio, indicating it may be undervalued. However, the decrease in earnings per share this quarter suggests potential challenges, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Kiniksa Pharmaceuticals has a P/E of 4.81 and experienced a decrease in earnings per share this quarter.
Kiniksa Pharmaceuticals has a low P/E ratio, indicating it may be undervalued. However, the decrease in earnings per share this quarter suggests potential challenges, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Ocuphire Pharma has a P/E of 4.99 and experienced a decrease in earnings per share this quarter.
Ocuphire Pharma has a low P/E ratio, indicating it may be undervalued. However, the decrease in earnings per share this quarter suggests potential challenges, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100